NNVC News & Events

The company said, "NanoViricides compares potential treatment options for Ebola Bundibugyo virus strain and finds that the Company's broad-spectrum antiviral drug candidate NV-387 is worthy of evaluation in this scenario. The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source, such as fruit bats. The outbreak which was declared a public health emergency of international concern by the WHO on May 16, 2026, is rapidly expanding, outpacing containment efforts, with over 900 suspected cases and over 220 deaths, in a high traffic region bordering the Democratic Republic of Congo, Uganda, and South Sudan and with 11 more nations in Africa at risk. There are no approved vaccines or treatments against the Bundibugyo virus. As such, the possible treatment options during the current expanding outbreak scenario must look at either other approved therapies that may not work, or look at new therapies that are at clinical stage. There were four drug candidates tested in a clinical trial in an Ebola Zaire outbreak, namely an antibody cocktail called ZMapp, another antibody cocktail called REGN-EB3, a monoclonal antibody developed from a survivor patient called mAb114, and a broad-spectrum nucleotide analog drug called Remdesivir. Of these, the more effective mAb114 and REGN-EB3 were approved as treatments for Ebola Zaire infection, and the effect of ZMapp and Remdesivir against standard of care was not evaluated in the PALM clinical trial. All of these four drugs require infusions, which is very difficult in a deadly disease such as Ebola that requires strong patient isolation protocols, and wherein protection of health care workers is of utmost important. Further, monoclonal antibodies are highly specific to the strain of virus and usually are not effective against unrelated strains. Recently, a drug candidate, obeldesivir, was developed related to remdesivir. Oral obeldesivir failed as a treatment for COVID-19 in a Phase III clinical trial. This clinical failure raises substantial doubts that obeldesivir would be of any benefit in Ebola Bundibugyo infection, since the clinical activity of obeldesivir indeed appears to be less than that of remdesivir, Remdesivir was approved for COVID-19, but not for Ebola Zaire. NV-387 was previously evaluated by the Company in animal models wherein a separate group of infected animals was treated with remdesivir to serve as a positive control. The increase in survival over untreated animals was 8.5 days for NV-387 IV, 4.4 days for NV-387 Oral, but only 2 days for Remdesivir IV in this uniformly lethal infection model for COVID-19. This indicates that NV-387 IV as well as NV-387 PO were substantially superior to Remdesivir. We believe these results of NV-387 being superior to Remdesivir as a treatment would hold for other viruses as well, including Ebola viruses."

NanoViricides emphasizes the need for a broad-spectrum, antiviral drug like NV-387 as another severe Ebolavirus outbreak has occurred in the Eastern part of DR Congo, with spillage across the border into Uganda. The company said, "Viruses are unlikely to escape NV-387 because no matter how much the viruses change, they still depend upon their interaction with sulfated proteoglycans for initial attachment to cells, which NV-387 mimics.In contrast, antibodies and vaccines are highly specific, and are readily escaped by viruses. Further, antibodies require a cold chain and must be given as infusions in patients. The equipment and facilities for the cold chain and for infusion itself in a high isolation setting are generally not available in remote areas. NV-387 is an oral medication that has excellent stability at room temperature, enabling ease of transport, distribution, and delivery to patient. NV-387 oral gummies dissolve naturally in the mouth and do not require tablet swallowing, which is difficult for children, seniors, and also patients with sore throat. If NV-387, as a broad-spectrum antiviral, is found to be effective against the Bundibugyo virus, it will likely be effective against all ebolaviruses or all filoviruses; that would be a game changer for pandemic preparedness."

NanoViricides entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 1,333,334 million common shares, together with accompanying warrants to purchase 1,333,334 common shares for gross proceeds of approximately $2M in a registered direct offering. The common shares are being sold in combination with an accompanying full warrant. Each whole warrant has an exercise price of $1.75 per share and will expire three years from the date of issuance. D. Boral Capital is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about May 18, 2026, subject to the satisfaction of customary closing conditions. The Company expects to receive aggregate gross proceeds of ~$2M from the Offering, before deducting placement agent fees and other related expenses.

The company said, "We reported that, as of March 31, 2026, we had cash and cash equivalent current assets balance of approximately $3.38 Million. In addition, we reported approximately $10.20 Million in total Assets including $6.53 Million of Net Property and Equipment assets. The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $1.07 Million. The net cash utilized during the nine months ended March 31, 2026 was approximately $5.58 Million. This included certain non-recurring expenditures including R&D expenditures in preparation for a Phase II clinical trial application. Based on budgeting considerations, we reported that we do not have sufficient funding in hand to continue operations through May 14, 2027, for our planned objectives that include a Phase II clinical trial of NV-387 for MPox infection in Central Africa, a Phase II clinical trial of NV-387 for Viral Acute and Severe Acute Respiratory Infections, and Preparation and pre-IND filing for a Phase II clinical trial of NV-387 for RSV indication in the USA. As such, we have focused on the objective , the Phase II Mpox clinical trial. We continue to have access to an "At-The-Market" common stock facility under a shelf registration, with D. Boral Capital, LLC, the sales agent. We also note that an additional gross cash financing of $6.25 Million would result into the Company if and when the Series A warrants from the November, 2025 financing are exercised. Additionally, we continue to have access to an available line of credit of $3 million provided by our founder and President Dr. Anil Diwan. No funds have been drawn on this facility as of now. At present, we have sufficient funding to execute and complete the Phase II clinical trial of NV-387 for MPox infection in DRC according to our plans and projections."